Contributor's Links: Trust Intelligence

I started trading cheap mining stocks as a Graduate Student in the Neureopsychology Lab of McGill's Allan Memorial Institute before the term "daytrading" was invented. In my spare time, I read everything on investing in the Business School library and I devoured their collection of ... more

ALL CONTRIBUTIONS

Omeros Derisked
Omeros has recently reported progress that derisks the company. The fundamental risk reduction has not been reflected in the excessively discounted share price.
Read
Omeros' Path To OMS7211 Approval
OMS721 just was awarded FDA Breakthrough Therapy Designation for yet another disorder; to treat patients at significant risk of dying after Hematopoietic Stem Cell Transplant.
Read
Provectus Phase III Melanoma Trial Results Earlier Than Planned?
Based upon pre-existing and clear data on safety & efficacy, it is very likely that the PVCT Phase III pivotal melanoma trial will demonstrate the safety and efficacy of PV-10 to the market and to prospective acquirers earlier than anticipated.
Read

Comments

Latest Comments
Provectus Phase III Melanoma Trial Results Earlier Than Planned?
4 years ago

Even more of a bargain at this point, but it is a waiting game for news. Q1'16 should see some, fundamental advance, although only time will tell market reaction.

In this article: PVCT
Provectus Phase III Melanoma Trial Results Earlier Than Planned?
5 years ago

Lots of things happening for Provectus and in a direction opposite the share price. Their Phase 3 trial has started and will be gaining momentum. See my latest, here: www.trustintelligence.com/.../viewtopic.php

New and probably stunningly good liver cancer data is due out in less than 6 weeks. Hints indicate that this will show efficacy that is way better than anything other drug available or in development. There are over a million people with liver cancer in the US. And with China having 55% of world primary liver cancer, the recently extended MOU with govt.-owned Sinopharm may soon be converted into an official license deal.

They just started talking with Brazil for a South American license and have a number of other deals they are working on. Should be a surprising summer for a stock that does not deserve to be so cheap!

In this article: PVCT
Provectus Phase III Melanoma Trial Results Earlier Than Planned?
6 years ago
You are welcome Kent. Hope you found the possibilities interesting. More to come.
In this article: PVCT
1 to 3 of 3 comments

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications